TABLE 3.
Treatment Outcomes. Progression Free Survival and Overall Survival Data are censored at the last follow-up.
| mTOR_C | mTOR_CT | mTOR_T | Overall | |
|---|---|---|---|---|
| Response | ||||
| CR / PR | 10 | 11 | 7 | 28 |
| SD | 8 | 6 | 3 | 17 |
| PD | 2 | 2 | - | 4 |
| Response Rates (%) | ||||
| ORR | 50.0 | 57.9 | 70.0 | 57.1 |
| DCR | 90.0 | 89.5 | 100.0 | 91.8 |
| Survival (months) | ||||
| mPFS* | 5.2 (3.8–6.6) | 4.9 (3.8–6.0) | 4.9 (2.0–10.0) | 4.9 (3.6–6.2) |
| mOS* | 7.2 (2.7–11.7) | 9.4 (4.6–14.2) | 12.1 (6.7–17.5) | 9.4 (6.6–12.2) |
| Survival Rates (%) | ||||
| 12-month PFS | 40.0 | 85.0 | 65.0 | 60.0 |
| 12-month OS | 55.0 | 70.0 | 75.0 | 55.0 |
| 24-month OS | 40.0 | 35.0 | 20.0 | 35.0 |
CR, Complete Response; PR, Partial Response, SD, Stable Disease; PD, Progressive Disease; ORR, Objective Response Rate; DCR, Disease Control Rate; PFS, Progression Free Survival; OS, Overall Survival; mPFS, median PFS, mOS: median OS. *values within parentheses indicate 95% Confidence Interval.